Published in Cell Immunol on October 24, 2007
Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy. J Heart Lung Transplant (2010) 1.35
Endothelial cells in allograft rejection. Transplantation (2008) 1.19
Red blood cell age and potentiation of transfusion-related pathology in trauma patients. Transfusion (2011) 1.05
The perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejection. Trends Mol Med (2015) 0.90
Peptide inhibitor of complement c1, a novel suppressor of classical pathway activation: mechanistic studies and clinical potential. Front Immunol (2014) 0.88
Chronic alloantibody mediated rejection. Semin Immunol (2011) 0.87
A novel method of measuring cardiac preservation injury demonstrates University of Wisconsin solution is associated with less ischemic necrosis than Celsior in early cardiac allograft biopsy specimens. J Heart Lung Transplant (2011) 0.85
Mesenchymal stem cells engineered to inhibit complement-mediated damage. PLoS One (2013) 0.82
Peptide Inhibitor of Complement C1 (PIC1) Rapidly Inhibits Complement Activation after Intravascular Injection in Rats. PLoS One (2015) 0.82
Memory B cells in transplantation. Transplantation (2015) 0.82
SALO, a novel classical pathway complement inhibitor from saliva of the sand fly Lutzomyia longipalpis. Sci Rep (2016) 0.81
Kidney and liver transplants from donors after cardiac death: initial experience at the London Health Sciences Centre. Can J Surg (2010) 0.76
Complement-Mediated Enhancement of Monocyte Adhesion to Endothelial Cells by HLA Antibodies, and Blockade by a Specific Inhibitor of the Classical Complement Cascade, TNT003. Transplantation (2017) 0.75
New concepts in alloimmune recognition. Cell Immunol (2007) 0.75
Natural adjuvants: endogenous activators of dendritic cells. Nat Med (1999) 7.10
Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell (2005) 5.90
Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant (2005) 5.87
Fcgamma receptors: old friends and new family members. Immunity (2006) 5.60
Significance of the positive crossmatch test in kidney transplantation. N Engl J Med (1969) 5.50
Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science (1990) 4.67
C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science (1996) 4.35
Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med (2002) 3.39
C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings. Am J Transplant (2006) 2.81
Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood (2003) 2.73
C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. J Immunol (1997) 2.69
Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med (1998) 2.69
Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med (1996) 2.67
Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest (1996) 2.51
Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest (2000) 2.45
Identification of the target self-antigens in reperfusion injury. J Exp Med (2006) 2.38
Complement in organ transplantation. Contributions to inflammation, injury, and rejection. Transplantation (1995) 2.36
Decay-accelerating factor modulates induction of T cell immunity. J Exp Med (2005) 2.34
Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem (1989) 2.20
C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J Clin Invest (2002) 2.11
Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc Natl Acad Sci U S A (2000) 2.10
Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion. Signal integration and NF-kappa B translocation. J Clin Invest (1995) 2.06
P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci U S A (1994) 2.00
C5a-induced expression of P-selectin in endothelial cells. J Clin Invest (1994) 1.93
Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immunol (2005) 1.89
C1q deficiency and autoimmunity: the effects of genetic background on disease expression. J Immunol (2002) 1.88
Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol (2000) 1.86
Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity (2003) 1.84
Recognition ligands on apoptotic cells: a perspective. J Leukoc Biol (2006) 1.78
Activation of the lectin pathway by natural IgM in a model of ischemia/reperfusion injury. J Immunol (2006) 1.78
Platelet activation leads to activation and propagation of the complement system. J Exp Med (2005) 1.76
Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation (2001) 1.70
Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2. J Clin Invest (2006) 1.69
The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol (2004) 1.65
Opsonization with C1q and mannose-binding lectin targets apoptotic cells to dendritic cells. J Immunol (2004) 1.64
Complement proteins C1q and MBL are pattern recognition molecules that signal immediate and long-term protective immune functions. Mol Immunol (2006) 1.61
The globular heads of C1q specifically recognize surface blebs of apoptotic vascular endothelial cells. J Immunol (2001) 1.59
Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest (2006) 1.57
Dendritic cell synthesis of C3 is required for full T cell activation and development of a Th1 phenotype. J Immunol (2006) 1.57
Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant (2003) 1.54
Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1. J Immunol (1995) 1.53
Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur J Immunol (2002) 1.52
Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice. J Clin Invest (2006) 1.51
Opsonization of apoptotic cells by autologous iC3b facilitates clearance by immature dendritic cells, down-regulates DR and CD86, and up-regulates CC chemokine receptor 7. J Exp Med (2002) 1.51
Linking innate and acquired immunity: divergent role of CD46 cytoplasmic domains in T cell induced inflammation. Nat Immunol (2002) 1.51
C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ishemia/reperfusion. J Immunol (2007) 1.45
Mannan-binding lectin recognizes structures on ischaemic reperfused mouse kidneys and is implicated in tissue injury. Scand J Immunol (2005) 1.44
Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol (1991) 1.42
A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney Int (2003) 1.41
IGM is required for efficient complement mediated phagocytosis of apoptotic cells in vivo. Autoimmunity (2005) 1.40
C1q and MBL, components of the innate immune system, influence monocyte cytokine expression. J Leukoc Biol (2006) 1.40
Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Natl Acad Sci U S A (2007) 1.39
Local extravascular pool of C3 is a determinant of postischemic acute renal failure. FASEB J (2006) 1.38
Cellular expression of the C5a anaphylatoxin receptor (C5aR): demonstration of C5aR on nonmyeloid cells of the liver and lung. J Immunol (1995) 1.38
Incidence of C4d stain in protocol biopsies from renal allografts: results from a multicenter trial. Am J Transplant (2005) 1.37
Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc (1987) 1.35
Holding T cells in check--a new role for complement regulators? Trends Immunol (2006) 1.30
Mannose-binding lectin binds IgM to activate the lectin complement pathway in vitro and in vivo. Immunobiology (2006) 1.30
The mannose-binding lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion injury. Am J Pathol (2004) 1.28
Specific binding of L-ficolin and H-ficolin to apoptotic cells leads to complement activation. Immunobiology (2005) 1.26
Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med (1995) 1.26
Accommodation: preventing injury in transplantation and disease. J Immunol (2004) 1.25
Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant (2005) 1.24
C4d deposition in acute rejection: an independent long-term prognostic factor. J Am Soc Nephrol (2002) 1.23
Maturation of dendritic cells abrogates C1q production in vivo and in vitro. Blood (2004) 1.20
The allogeneic T and B cell response is strongly dependent on complement components C3 and C4. Transplantation (2001) 1.20
Interactions of the extracellular matrix proteoglycans decorin and biglycan with C1q and collectins. J Immunol (2005) 1.19
Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells. Blood (2005) 1.19
Chronic cardiac transplant arteriopathy in mice: relationship of alloantibody, C4d deposition and neointimal fibrosis. Am J Transplant (2007) 1.18
The differing roles of the classical and mannose-binding lectin complement pathways in the events following skeletal muscle ischemia-reperfusion. J Immunol (2006) 1.17
BCA-1/CXCL13 expression is associated with CXCR5-positive B-cell cluster formation in acute renal transplant rejection. Kidney Int (2005) 1.16
Lymphoid neogenesis in chronic rejection: evidence for a local humoral alloimmune response. Proc Natl Acad Sci U S A (2005) 1.16
CD46 plays a key role in tailoring innate immune recognition of apoptotic and necrotic cells. J Biol Chem (2005) 1.15
A further link between innate and adaptive immunity: C3 deposition on antigen-presenting cells enhances the proliferation of antigen-specific T cells. Int Immunol (1998) 1.14
Antibody and complement in transplant vasculopathy. Circ Res (2007) 1.12
In situ localization of C3 synthesis in experimental acute renal allograft rejection. Am J Pathol (2000) 1.12
Ischemia/reperfusion injury in human kidney transplantation: an immunohistochemical analysis of changes after reperfusion. Am J Pathol (1998) 1.11
Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition. Blood (1999) 1.10
Lymphoid neogenesis in murine cardiac allografts undergoing chronic rejection. Am J Transplant (2005) 1.09
Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154. J Clin Invest (2006) 1.08
Endothelial cell activation by pore-forming structures: pivotal role for interleukin-1alpha. Circulation (2000) 1.04
Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens (2002) 1.02
C4d deposition and clearance in cardiac transplants correlates with alloantibody levels and rejection in rats. Am J Transplant (2006) 1.00
Distinct transcriptional changes in donor kidneys upon brain death induction in rats: insights in the processes of brain death. Am J Transplant (2004) 0.99
Complement component C3d-antigen complexes can either augment or inhibit B lymphocyte activation and humoral immunity in mice depending on the degree of CD21/CD19 complex engagement. J Immunol (2005) 0.99
ABO-incompatible kidney transplantation: initial immunopathologic evaluation. Transplant Proc (1987) 0.98
C6 produced by macrophages contributes to cardiac allograft rejection. Am J Pathol (1999) 0.98
Association between mannose-binding lectin levels and graft survival in kidney transplantation. Am J Transplant (2005) 0.98
Activation of inflammatory mediators in rat renal isografts by donor brain death. Transplantation (2000) 0.96
Fc(gamma) receptor cross-linking induces peripheral blood mononuclear cell monocyte chemoattractant protein-1 expression: role of lymphocyte Fc(gamma)RIII. J Immunol (1997) 0.95
Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine. Transplantation (2005) 0.95
Platelet transfusions are associated with the development of anti-major histocompatibility complex class I antibodies in patients with left ventricular assist support. J Heart Lung Transplant (1998) 0.94
Complement activation by necrotic cells in normal plasma environment compares to that by late apoptotic cells and involves predominantly IgM. Eur J Immunol (2004) 0.94
Chronic antibody mediated rejection of renal allografts: pathological, serological and immunologic features in nonhuman primates. Am J Transplant (2006) 0.92
Complement-induced expression of chemokine genes in endothelium: regulation by IL-1-dependent and -independent mechanisms. J Immunol (1998) 0.92
Sequential cellular and molecular kinetics in acutely rejecting renal allografts in rats. Transplantation (1997) 0.92
Regulation of monocyte survival in vitro by deposited IgG: role of macrophage colony-stimulating factor. J Immunol (1999) 0.91
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science (2006) 10.25
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol (2009) 6.43
Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79
A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. N Engl J Med (2009) 4.54
Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res (2008) 3.67
Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci U S A (2008) 2.99
Robot-assisted renal transplantation in the retroperitoneum. Transpl Int (2014) 2.31
TGFβ receptor mutations impose a strong predisposition for human allergic disease. Sci Transl Med (2013) 2.08
Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res (2002) 2.07
BIN1 is reduced and Cav1.2 trafficking is impaired in human failing cardiomyocytes. Heart Rhythm (2011) 1.85
T1 Mapping in cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy. Radiology (2012) 1.83
Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation (2008) 1.82
Emphysematous cholecystitis. Am J Surg (2010) 1.68
A rasopathy phenotype with severe congenital hypertrophic obstructive cardiomyopathy associated with a PTPN11 mutation and a novel variant in SOS1. Am J Med Genet A (2012) 1.62
sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes (2013) 1.61
Regulation of platelet granule exocytosis by S-nitrosylation. Proc Natl Acad Sci U S A (2005) 1.52
A Pkd1-Fbn1 genetic interaction implicates TGF-β signaling in the pathogenesis of vascular complications in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2013) 1.49
A central role of plasmin in cardiac injury initiated by fetal exposure to maternal anti-Ro autoantibodies. Rheumatology (Oxford) (2013) 1.41
Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Natl Acad Sci U S A (2007) 1.39
Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia. Pain (2010) 1.38
Histopathologic findings in ascending aortas from individuals with Loeys-Dietz syndrome (LDS). Am J Surg Pathol (2009) 1.34
Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts. J Immunol (2008) 1.33
Update on cardiac transplantation pathology. Arch Pathol Lab Med (2007) 1.33
The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2012) 1.32
Decreased S-nitrosylation of tissue transglutaminase contributes to age-related increases in vascular stiffness. Circ Res (2010) 1.30
IL-1β-driven neutrophilia preserves antibacterial defense in the absence of the kinase IKKβ. Nat Immunol (2010) 1.27
2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol (2011) 1.24
Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant (2005) 1.24
Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the beta3-adrenoreceptor. J Mol Cell Cardiol (2009) 1.24
Tissue- and age-dependent expression of RNA-binding proteins that influence mRNA turnover and translation. Aging (Albany NY) (2009) 1.20
In vivo platelet-endothelial cell interactions in response to major histocompatibility complex alloantibody. Circ Res (2008) 1.17
Non-complement- and complement-activating antibodies synergize to cause rejection of cardiac allografts. Am J Transplant (2004) 1.14
HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size. Circ Res (2005) 1.14
Fatal outcome of a calcified amorphous tumor of the heart (cardiac CAT). Cardiovasc Pathol (2006) 1.14
Cutting edge: Generation of colitogenic Th17 CD4 T cells is enhanced by IL-17+ γδ T cells. J Immunol (2011) 1.13
Membrane attack complex contributes to destruction of vascular integrity in acute lung allograft rejection. J Immunol (2002) 1.13
Mini-laparotomy implantation of peritoneal dialysis catheters: outcome and rescue. Perit Dial Int (2010) 1.13
Antibody and complement in transplant vasculopathy. Circ Res (2007) 1.12
Surgery for gastrointestinal stromal tumors of the duodenum. Ann Surg Oncol (2009) 1.12
Enhanced proliferation of cultured human vascular smooth muscle cells linked to increased function of RNA-binding protein HuR. J Biol Chem (2005) 1.12
Extranodal Rosai-Dorfman disease involving the heart: report of two cases. Cardiovasc Pathol (2009) 1.11
MicroRNA profiling of diverse endothelial cell types. BMC Med Genomics (2011) 1.11
A comprehensive histopathological evaluation of vascular medial fibrosis: insights into the pathophysiology of arterial stiffening. Atherosclerosis (2009) 1.09
Solid pseudopapillary neoplasms of the pancreas: is there a pathologic basis for the observed gender differences in incidence? Surgery (2005) 1.08
The involvement of FcR mechanisms in antibody-mediated rejection. Transplantation (2007) 1.08
Inhibition of N-ethylmaleimide-sensitive factor protects against myocardial ischemia/reperfusion injury. Circ Res (2007) 1.08
GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas. Hum Pathol (2013) 1.06
Benign cardiac tumors and tumorlike conditions. Ann Diagn Pathol (2010) 1.06
Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection. Transplant Rev (Orlando) (2009) 1.03
Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy. Hum Pathol (2011) 1.02
New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy--a report of 2 cases. Hum Pathol (2007) 1.00
Signal transducer and activator of transcription 3alpha and specificity protein 1 interact to upregulate intercellular adhesion molecule-1 in ischemic-reperfused myocardium and vascular endothelium. Arterioscler Thromb Vasc Biol (2005) 0.99
Anaerobic vs aerobic pathways of carbonyl and oxidant stress in human lens and skin during aging and in diabetes: A comparative analysis. Free Radic Biol Med (2010) 0.98
Decreased capacity of immune cells to cause tissue injury mediates kidney ischemic preconditioning. J Immunol (2006) 0.96
Absence of mannose-binding lectin prevents hyperglycemic cardiovascular complications. Am J Pathol (2011) 0.96
Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer. Hum Pathol (2010) 0.96
Postmortem cardiac tissue maintains gene expression profile even after late harvesting. BMC Genomics (2012) 0.95
Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation (2002) 0.95
B cells and plasma cells in coronaries of chronically rejected cardiac transplants. Transplantation (2010) 0.94
Myocardial citrullination in rheumatoid arthritis: a correlative histopathologic study. Arthritis Res Ther (2012) 0.94
Color deconvolution for the analysis of tissue microarrays. Anal Quant Cytol Histol (2009) 0.93
Exercise, vascular stiffness, and tissue transglutaminase. J Am Heart Assoc (2014) 0.93
Causes and histopathology of ascending aortic disease in children and young adults. Cardiovasc Pathol (2010) 0.93
Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation (2007) 0.92
Tissue inhibitor of matrix metalloproteinase-3 levels in the extracellular matrix of lung, kidney, and eye increase with age. J Histochem Cytochem (2008) 0.92
Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000-2009. Circ Heart Fail (2013) 0.92
Platelets contribute to allograft rejection through glutamate receptor signaling. J Immunol (2010) 0.91
Platelets present antigen in the context of MHC class I. J Immunol (2012) 0.91
Gap junction remodeling in a case of arrhythmogenic right ventricular dysplasia due to plakophilin-2 mutation. J Cardiovasc Electrophysiol (2008) 0.91
Robust immunohistochemical staining of several classes of proteins in tissues subjected to autolysis. J Histochem Cytochem (2007) 0.90
Terminal complement components mediate release of von Willebrand factor and adhesion of platelets in arteries of allografts. Transplantation (2005) 0.90
The production of red blood cell alloantibodies in mice transfused with blood from transgenic Fyb-expressing mice. Transfusion (2006) 0.89
White blood cell inactivation after treatment with riboflavin and ultraviolet light. Transfusion (2010) 0.88
Cutting edge: IFN-γR signaling in non-T cell targets regulates T cell-mediated intestinal inflammation through multiple mechanisms. J Immunol (2014) 0.88
An extraribosomal function of ribosomal protein L13a in macrophages resolves inflammation. J Immunol (2013) 0.88
Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model. PLoS One (2013) 0.88
Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9. Breast Cancer Res (2008) 0.87
Heterogeneity of Bcl-2 expression in metastatic breast carcinoma. Mod Pathol (2010) 0.86
Expression of cathepsin K and tartrate-resistant acid phosphatase is not confined to osteoclasts but is a general feature of multinucleated giant cells: systematic analysis. Rheumatology (Oxford) (2013) 0.85
Antibody and complement mediated injury in transplants following sensitization by allogeneic blood transfusion. Transplantation (2006) 0.85
A novel method of measuring cardiac preservation injury demonstrates University of Wisconsin solution is associated with less ischemic necrosis than Celsior in early cardiac allograft biopsy specimens. J Heart Lung Transplant (2011) 0.85
Cardiac transplantation in arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol (2012) 0.84
A TLR5 agonist inhibits acute renal ischemic failure. J Immunol (2011) 0.84
Caloric restriction in leptin deficiency does not correct myocardial steatosis: failure to normalize PPAR{alpha}/PGC1{alpha} and thermogenic glycerolipid/fatty acid cycling. Physiol Genomics (2011) 0.84
Hapten application to the skin induces an inflammatory program directing hapten-primed effector CD8 T cell interaction with hapten-presenting endothelial cells. J Immunol (2011) 0.83
Alloantibody induced platelet responses in transplants: potent mediators in small packages. Hum Immunol (2012) 0.83
Prognostic value of left ventricular apical tissue removed for HeartMate II left ventricular assist device placement. Cardiovasc Pathol (2008) 0.83
Phosphodiesterase-5A (PDE5A) is localized to the endothelial caveolae and modulates NOS3 activity. Cardiovasc Res (2011) 0.83
De novo malignancy is associated with renal transplant tourism. Kidney Int (2011) 0.82
Ribosomal protein L13a deficiency in macrophages promotes atherosclerosis by limiting translation control-dependent retardation of inflammation. Arterioscler Thromb Vasc Biol (2014) 0.82
Giant cell myocarditis depicted by cardiac magnetic resonance imaging. J Comput Assist Tomogr (2005) 0.81
Anti-human leukocyte antigen antibodies, vascular C4d deposition and increased soluble c4d in broncho-alveolar lavage of lung allografts. Transplantation (2008) 0.81
Reversible cardiomyopathy caused by administration of interferon alpha. Nat Clin Pract Cardiovasc Med (2005) 0.80
Cardiac allograft vasculopathy: do adipocytes bridge alloimmune and metabolic risk factors? Curr Opin Organ Transplant (2010) 0.80
Recommendations for processing cardiovascular surgical pathology specimens: a consensus statement from the Standards and Definitions Committee of the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology. Cardiovasc Pathol (2011) 0.80
Stat3β mitigates development of atherosclerosis in apolipoprotein E-deficient mice. J Mol Med (Berl) (2013) 0.80